Industry news that matters to you.  Learn more

Opinions of 18 World-renowned Experts Contained in Consensus Paper on Role of Cardiac Biomarker ST2 in Heart Failure Care

Reading time: 2 – 3 minutes

Critical Diagnostics recently reported that The American Journal of Cardiology released an online version of a comprehensive consensus paper discussing the evidence base behind the evolving role of the cardiac biomarker ST2 and its appropriate uses in the management of patients with heart failure and related cardiac diseases.

“Given the rapid rise in scientific reports discussing ST2 and heart disease, we felt it appropriate to propose an international working group focused on appropriate use of ST2 across a wide range of topics,” note the paper’s leader authors, James L Januzzi, MD, PhD, Division of Cardiology, Massachusetts General Hospital, Boston, MA., and Antoni Bayes-Genis,MD, PhD , Department of Cardiology, Hospital universitari Germans Trias i Pujol.

The paper stems from an International ST2 Consensus Panel of experts from around the world that gathered in March 2014 in Washington, DC., to discuss and update the rising number of studies focused on the use of ST2.

As the authors point out, “Despite the well-documented successes and strengths of natriuretic peptides, there is plenty of room for improvement in the way we evaluate and risk-stratify patients with or at risk for HF using biomarkers. Although a large number of candidate biomarkers have been evaluated to help fill this gap, few have survived the rigorous studies that are a prerequisite to allow for translation into the clinical realm[1],[2]. It now appears clear that ST2 (reflecting myocardial fibrosis and remodeling) is a biomarker that has successfully navigated this course and is recently emerging as a reliable tool for patient care.

“The recent 2013 AHA/ACC Guidelines for the Management of Heart Failure give a recommendation for the measurement of ST2 in acute and ambulatory HF patients, noting that ST2 is not only predictive of hospitalization and death in patients with HF, but is also additive to the natriuretic peptides in its prognostic value[3]. The body of evidence surrounding ST2 in both acute and chronic heart failure is growing rapidly, and with this, its clinical use has increased.[4]”

To access to the paper, go to: http://www.ajconline.org/issue/S0002-9149(15)X0003-8

Source: Critical Diagnostics